CLOUDBREAK-B (02592) surged more than 4%, reaching HK$8.58 by the time of writing, with a trading volume of HK$11.82 million. The company announced that its wholly-owned U.S. subsidiary, Cloudbreak USA, has scheduled a post-Phase 2 clinical trial meeting with the U.S. Food and Drug Administration (FDA) on December 10, 2025. The meeting will focus on the clinical-stage drug candidate CBT-004.
This post-Phase 2 meeting marks a critical milestone in CBT-004's development, as it will discuss potential Phase 3 clinical trial plans and requirements for a New Drug Application (NDA).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments